Northwest Biomedical Laboratories

Northwest Biotherapeutics is a clinical-stage biotechnology company focused on developing personalized cancer vaccines using its proprietary DCVax platform. The company's lead product candidate, DCVax-L, is a dendritic cell-based immunotherapy designed to treat glioblastoma multiforme (GBM) and has completed a large Phase 3 clinical trial with results published in JAMA Oncology. Northwest Biotherapeutics also develops DCVax-Direct, which is intended for the treatment of various inoperable solid tumors. The company's approach involves using a patient's own dendritic cells, primed with tumor antigens, to stimulate a robust immune response against the cancer.